SecBot SecBot
6-K ·Filed Sep 2, 2026

PPBT

PURPLE BIOTECH LTD.
NEUTRAL
Impact 3/10
Horizonweeks Processed2mo ago SEC0001213900-26-096443
Notable filing: 6-K
Actionable Insight • Neutral

This patent allowance is a routine IP event for a pre-revenue clinical-stage biotech with a $3M market cap. No financial data or clinical catalysts are provided. Monitor for future partnering announcements or clinical trial updates on IM1240, but the filing itself does not warrant a trading action.

DirectionNeutral
Confidencemedium
Horizonweeks

How the stock moved after the report

NEUTRAL VIEWSTOCK BELOW ENTRY AT T+20
Entry
$1.98
T+0 close · Sep 2, 2026 · via day close
Latest settled
−23.23%
T+20 · $1.52 · next T+60 in 10d
Vs SPY
−23.15%
α at T+20
Latest observation
−6.08%
T+52 · FF3 residual α
  1. T+0 · Sep 2 $1.98entry
  2. T+1 · 3mo ago 0.00%α −1.05% · $1.98
  3. T+5 · 2mo ago −12.12%α −11.16% · $1.74
  4. T+20 · 7w ago −23.23%α −23.15% · $1.52
  5. T+52 · todayOpen
  6. T+60 · in 10d Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Purple Biotech announced a USPTO Notice of Allowance for a patent covering tri-specific antibody constructs and methods of use, strengthening IP protection for its CAPTN-3 modular platform. This is a routine IP milestone for a clinical-stage company with a $3M market cap and no revenue, providing no near-term financial catalyst.

Key Facts

  • USPTO issued Notice of Allowance for patent application covering tri-specific antibody constructs and methods of use.
  • Patent strengthens IP protection for CAPTN-3 modular platform for conditionally activated multispecific antibodies.
  • Lead candidate IM1240 is advancing toward the clinic; second candidate IM1305 is in preclinical development.
  • Company market cap is approximately $3M with no reported revenue from the filing.

Financial Impact

No financial figures disclosed; patent allowance is an IP milestone with no immediate revenue or cost impact.

Risk Factors

  • No revenue or near-term commercialization path disclosed.
  • Lead candidate IM1240 is still pre-clinical; clinical-stage assets (CM24, NT219) require partnering or investment to advance.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations

Investment Themes

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
6-K Filing (Primary)0001213900-26-096443
Document: ea0304192-6k_purple.htm0001213900-26-096443
Document: 0001213900-26-096443-index-headers.html0001213900-26-096443
Document: 0001213900-26-096443-index.html0001213900-26-096443
Document: 0001213900-26-096443.txt0001213900-26-096443

US Market Status

Market Closed · Opens in 6h 37m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Sep 2, 2026